A common challenge in older adults: Classification, overlap, and therapy of depression and dementia
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Late‐life depression is frequently associated with cognitive impairment. Depressive symptoms are often associated with or even precede a dementia syndrome. Moreover, depressive disorders increase the risk of persistence for mild cognitive impairment and dementia. Here, we present both the current state of evidence and future perspectives regarding the integration and value of clinical assessments, neuropsychological, neurochemical, and neuroimaging biomarkers for the etiological classification of the dementia versus the depression syndrome and for the prognosis of depression relating to dementia risk. Finally, we summarize the existing evidence for both pharmacotherapy and psychotherapy of depression in demented patients. There is an urgent need for large‐scale collaborative research to elucidate the role and interplay of clinical and biological features in elderly individuals with depressive disorders who are at elevated risk for developing dementia. To overcome barriers for successful drug development, we propose the introduction of the precision medicine paradigm to this research field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 2×
“[16] Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al.”
BackgroundMethodThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationFrontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“Reduced plasma BDNF levels have been observed both in animal models of depression [54] as well as in patients with depression [55,56] and AD [57,58].”
BackgroundCornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Alexopoulos, G. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66665-2 · Cited by 2,024
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 2×
“[40] Blennow K, Hampel H, Weiner M, Zetterberg H.”
BackgroundSelf-citation'Vascular Depression' Hypothesis
Alexopoulos, G. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220033006 · Cited by 1,843
Hippocampal volume and depression: a meta-analysis of MRI studies
Videbech, P., & Ravnkilde, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1957 · Cited by 1,590 · cited 1×
“Notably, atrophy of the hippocampus is a well-characterized brain alteration detected both in AD [36] and in patients with depression [37,38].”
BackgroundDepression and risk of developing dementia
Byers, A. L., & Yaffe, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.60 · Cited by 1,265 · cited 2×
“In this setting, depression can be a risk factor, a prodrome, or a consequence of dementia [25].”
Backgroundfor the ENIGMA-Major Depressive Disorder Working Group, Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.69 · Cited by 1,172 · cited 2×
“Studies comparing the extent of hippocampus atrophy in late-onset depression and AD typically report substantially more pronounced atrophy in AD [92].”
BackgroundPsychotherapy for depression in adults: A meta-analysis of comparative outcome studies.
Cuijpers, P., van Straten, A., Andersson, G., & van Oppen, P. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013075 · Cited by 1,050 · cited 1×
“[126] Cuijpers P, van Straten A, Andersson G, van Oppen P.”
BackgroundNonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy
Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., del Ser, T., Woods, B., Beck, C., Auer, S., Lai, C., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000316119 · Cited by 937
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 2×
“Reduced plasma BDNF levels have been observed both in animal models of depression [54] as well as in patients with depression [55,56] and AD [57,58].”
BackgroundMRI-defined vascular depression
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.497 · Cited by 770
Inflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706 · cited 2×
“[52] Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al.”
BackgroundLopez, O. L., Jagust, W. J., DeKosky, S. T., Becker, J. T., Fitzpatrick, A., Dulberg, C., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1385 · Cited by 618
Karege, F., Vaudan, G., Schwald, M., Perroud, N., & La Harpe, R. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.12.020 · Cited by 600
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Amnestic MCI or prodromal Alzheimer's disease?
Dubois, B., & Albert, M. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00710-0 · Cited by 543
Self-citationBanerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 3×
“As reviewed recently by Leong [105], several randomized placebo-controlled interventions reported negative outcomes for antidepressant efficacy in dementia: with sertraline (95 mg daily) and mirtazapine (30 mg daily) for 13 weeks, assessed by CSDD in 326 patients [106]; sertraline (93 mg daily) for 24 weeks, assessed…”
BackgroundMethodCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2014) · World Psychiatry · doi:10.1002/wps.20089 · Cited by 424 · cited 1×
“[120] Cuijpers P, Sijbrandij M, Sander L, Koole SL, Andersson G, Beekman AT, et al.”
BackgroundSelf-citationA Review of the Relationship between Proinflammatory Cytokines and Major Depressive Disorder
Young, J. J., Bruno, D., & Pomara, N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.07.032 · Cited by 422
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398 · cited 2×
“In contrast, positive outcomes were reported for the following randomized placebo controlled trials with sertraline (95 mg daily) for 12 weeks, assessed by CSDD and HAM-D in 44 patients [112]; moclobemide (maximum 400 mg daily) for 6 weeks, assessed by HAM-D in 511 demented patients [113]; clomipramine (maximum 100 mg…”
BackgroundLate-life depression, mild cognitive impairment, and dementia
Richard, E., Reitz, C., Honig, L. H., Schupf, N., Tang, M. X., Manly, J. J., Mayeux, R., Devanand, D., & Luchsinger, J. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.603 · Cited by 389 · cited 2×
“[63] Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, et al.”
BackgroundRecurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
Dotson, V. M., Beydoun, M. A., & Zonderman, A. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62124 · Cited by 385
Nyth, A. L., & Gottfries, C. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.894 · Cited by 379
Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · cited 1×
“[50] Rojo LE, Fern andez JA, Maccioni AA, Jimenez JM,”
BackgroundInflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342 · cited 1×
“Moreover, proinflammatory cytokines overexpression is supposed to interfere with the serotonin metabolism, thereby decreasing both synaptic plasticity and hippocampal neurogenesis [42,49].”
BackgroundPinquart, M., Duberstein, P. R., & Lyness, J. M. (2007) · Aging & Mental Health · doi:10.1080/13607860701529635 · Cited by 328 · cited 1×
“[129] Pinquart M, Duberstein PR, Lyness JM.”
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · cited 2×
“[87] Bay-Richter C, Linderholm KR, Lim CK, SamuelssonM, Tr€askman-”
BackgroundDepression gets old fast: do stress and depression accelerate cell aging?
Wolkowitz, O. M., Epel, E. S., Reus, V. I., & Mellon, S. H. (2010) · Depression and Anxiety · doi:10.1002/da.20686 · Cited by 298
Psychiatric Symptoms Vary With the Severity of Dementia in Probable Alzheimer's Disease
Lopez, O. L., Becker, J. T., Sweet, R. A., Klunk, W., Kaufer, D. I., Saxton, J., Habeych, M., & DeKosky, S. T. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.3.346 · Cited by 286 · cited 3×
“A concomitant diagnosis of MCI has been reported in 25% to 50% of patients with late-life depression [64–66], compared to a 3% to 6% prevalence of MCI in community-based samples [11,67].”
BackgroundNelson, J. C., & Devanand, D. P. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03355.x · Cited by 284
Nebes, R. D., Pollock, B. G., Houck, P. R., Butters, M. A., Mulsant, B. H., Zmuda, M. D., & Reynolds, C. F. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00085-7 · Cited by 275
Self-citationAnxiety, depression and psychosis in vascular dementia: prevalence and associations
Ballard, C., Neill, D., O’Brien, J., McKeith, I. G., Ince, P., & Perry, R. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00057-9 · Cited by 257 · cited 1×
“[14] Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R.”
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250 · cited 2×
“As reviewed recently by Leong [105], several randomized placebo-controlled interventions reported negative outcomes for antidepressant efficacy in dementia: with sertraline (95 mg daily) and mirtazapine (30 mg daily) for 13 weeks, assessed by CSDD in 326 patients [106]; sertraline (93 mg daily) for 24 weeks, assessed…”
BackgroundMethodPsychotherapeutic treatments for older depressed people
Wilson, K., Mottram, P. G., & Vassilas, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004853.pub2 · Cited by 224
Antidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214
Sheline, Y. I., Price, J. L., Vaishnavi, S. N., Mintun, M. A., Barch, D. M., Epstein, A. A., Wilkins, C. H., Snyder, A. Z., Couture, L., Schechtman, K., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010175 · Cited by 213 · cited 1×
“[33] Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM,”
BackgroundA Systematic Review and Meta-Analysis of Magnetic Resonance Imaging Studies in Late-Life Depression
Sexton, C. E., Mackay, C. E., & Ebmeier, K. P. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.10.019 · Cited by 210 · cited 1×
“4 the hippocampus, ultimately increasing the vulnerability to depression [17].”
BackgroundPinquart, M., Duberstein, P. R., & Lyness, J. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1493 · Cited by 204 · cited 1×
“[121] Pinquart M, Duberstein PR, Lyness JM.”
Hippocampal volume reduction and HPA-system activity in major depression
Colla, M., Kronenberg, G., Deuschle, M., Meichel, K., Hagen, T., Bohrer, M., & Heuser, I. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.06.011 · Cited by 200 · cited 2×
“Notably, atrophy of the hippocampus is a well-characterized brain alteration detected both in AD [36] and in patients with depression [37,38].”
BackgroundReynolds, C. F., Butters, M. A., Lopez, O., Pollock, B. G., Dew, M. A., Mulsant, B. H., Lenze, E. J., Holm, M., Rogers, J. C., Mazumdar, S., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.184 · Cited by 171 · cited 2×
“Even the addition of a cholinesterase inhibitor in depressed patients showed only a small effect on concurrent cognitive impairment and on the conversion rate to dementia syndrome but with increased risk of recurrence of depression [118].”
BackgroundSelf-citationMagai, C., Kennedy, G., Cohen, C. I., & Gomberg, D. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00009 · Cited by 143
Major depression, cognitive dysfunction and Alzheimer's disease: Is there a link?
Sierksma, A. S. R., van den Hove, D. L. A., Steinbusch, H. W. M., & Prickaerts, J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.021 · Cited by 139
Kirkham, J. G., Choi, N., & Seitz, D. P. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4358 · Cited by 136
Diniz, B. S., Sibille, E., Ding, Y., Tseng, G., Aizenstein, H. J., Lotrich, F., Becker, J. T., Lopez, O. L., Lotze, M. T., Klunk, W. E., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.76 · Cited by 116 · cited 3×
“[72] Diniz BS, Sibille E, Ding Y, Tseng G, Tseng G, Aizenstein HJ, et al.”
BackgroundResultInfluentialSelf-citationSepehry, A. A., Lee, P. E., Hsiung, G. Y. R., Beattie, B. L., & Jacova, C. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0012-5 · Cited by 94 · cited 1×
“In summary, well-controlled studies, systematic reviews and meta-analyses [104,105,115,116] have shown no reliable and convincing efficacy of antidepressants in patients with dementia and co-occurring depressive disorders.”
Background
Cited by
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172
Antidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
(2022) · doi:10.1016/j.biopsych.2022.08.026 · Cited by 113
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Electroconvulsive Therapy in Geriatric Psychiatry
Meyer, J. P., Swetter, S. K., & Kellner, C. H. (2018) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.10.007 · Cited by 27
Metadata
- Authors
- Leyhe, T., Reynolds, C. F., Melcher, T., Linnemann, C., Klöppel, S., Blennow, K., Zetterberg, H., Dubois, B., Lista, S., & Hampel, H.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-09-28
- Volume
- 13
- Issue
- 1
- Pages
- 59-71
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2526628642
- Cited by
- 165
- References
- 56
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.